Nexalin Technology vs QTREX Quantum
NXL and QTEX side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How NXL and QTEX compare
Nexalin Technology keeps more of each dollar of sales as profit, with a net margin of −4139% compared with −4574% at QTREX Quantum.
Nexalin Technology scores higher on the StockData Score (7 against 5 for QTREX Quantum), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | NXL | QTEX |
|---|---|---|
| Size and price | ||
| Market cap | $33.1M | – |
| Share price | $1.50 | $1.09 |
| Change, 1 year | −95.4% | 15.8% |
| Change, 5 years | – | −67.0% |
| Beta (5Y) | 2.79 | – |
| Employees | 8 | 30 |
| StockData Score | ||
| Total score | 7 (better) | 5 |
| Valuation score | 0 | 0 |
| Growth score | 2 (better) | 0 |
| Performance score | 0 | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 152× | – |
| P/B | 21.8× | – |
| Growth | ||
| Revenue growth (TTM) | 24.2% | – |
| Profitability | ||
| Gross margin | 86.2% (better) | 0.69% |
| Operating margin | −4203% (better) | −4714% |
| Net margin | −4139% (better) | −4574% |
| FCF margin | – | −3448% |
| Return on equity | −240% | −220% (better) |
| Return on invested capital | −2105% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 1.25 | 2.00 (better) |
| Altman Z-score | −41.74 | – |
| Piotroski F-score | 5 (better) | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 0.13% | 7.5% |
| Held by insiders | 22.3% | 27.8% |
| Insider net buying, 12 months | – | −$218K |
| Short interest, % of float | 0.07% | 13.8% |
Go deeper
- NXL stock overview
- NXL income statement
- NXL valuation and score
- QTEX stock overview
- QTEX income statement
- QTEX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.